2023-03826. Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Scottsdale Research Institute, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 25, 2023. Such persons may also file a written request for a hearing on the application on or before April 25, 2023.

    ADDRESSES:

    The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on January 10, 2023, Scottsdale Research Institute, 12815 North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Start Printed Page 11958

    Controlled substanceDrug codeSchedule
    Marihuana Extract7350I
    Marihuana7360I
    Tetrahydrocannabinols7370I

    The company plans to bulk manufacture the listed controlled substances to support clinical trials and distribution to their customers for research purposes. No other activities for these drug codes are authorized for this registration.

    Start Signature

    Matthew Strait,

    Deputy Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2023-03826 Filed 2-23-23; 8:45 am]

    BILLING CODE P

Document Information

Published:
02/24/2023
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2023-03826
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 25, 2023. Such persons may also file a written request for a hearing on the application on or before April 25, 2023.
Pages:
11957-11958 (2 pages)
Docket Numbers:
Docket No. DEA-1150
PDF File:
2023-03826.pdf